Martha Rodríguez-Morán

Martha Rodríguez-Morán

Auto-generated profile, based on publicly available information

Martha Rodríguez-Morán

A Biomedical Research Unit, Mexican Social Security Institute , Durango , Dgo , México

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008
Verified
Journal Article
Closed access
LBLazaro Barragán-Rodríguez
Lazaro Barragán-Rodríguez
MRMartha Rodríguez-Morán
Martha Rodríguez-Morán
Fernando Guerrero-RomeroFernando Guerrero-Romero
Fernando Guerrero-Romero

12 May 2010 in Magnesium Research
Verified
Journal Article
Closed access
HRHeriberto Rodriguez-Hernandez
Heriberto Rodriguez-Hernandez
MCMiriam Cervantes-Huerta
Miriam Cervantes-Huerta
MRMartha Rodriguez-Moran
Martha Rodriguez-Moran
Fernando Guerrero-RomeroFernando Guerrero-Romero
Fernando Guerrero-Romero
To evaluate the effect of oral supplementation with magnesium chloride on the systemic and hepatic inflammation, 38 non-hypertensive obese women aged 30 to 65 years were allocated into groups with and without hypomagnesemia. Hypomagnesemic women drank 50 mL of 5% solution of MgCl2 equivalent to 450 mg of elemental magnesium. Low-carbohydrate diets and physical activity were indicated for women in both groups. Chronic diarrhea, alcohol intake, use of diuretics, previous oral magnesium supplementation, hepatic disease, and renal damage were exclusion criteria. Hypomagnesemia is defined by serum magnesium concentrationsor=40 U/L, and systemic inflammation by serum high-sensitivity C reactive protein (hs-CRP) concentration>or=3 mg/L. At baseline (p=0.06) and final of follow-up (p=0.80), there were no significant differences by body mass index between the groups in the study. In the same way, at baseline ALT (48.1+/-25.5 and 34.6+/-24.1 U/L, p=0.14) and hs-CRP (9.4+/-6.0 and 7.9+/-5.9 mg/dL, p=0.47) levels were similar in the supplemented and non-supplemented women. In the magnesium group, ALT (24.3+/-10.3 and 34.8+/-13.6 U/L, p=0.02) levels, but not hs-CRP (5.2+/-1.9 and 8.0+/-5.6 mg/L, p=0.08) reached significantly lower levels, in the fourth month of treatment, than in women in the control group. The adjusted odds ratios between the improvement in serum magnesium and reduction in ALT and hs-CRP levels were 0.56 (95% CI: 0.3-0.9) and 0.93 (95% CI: 0.6-29.9), respectively. Results of this study show that in hypomagnesemic obese women, oral supplementation with magnesium chloride reduces plasma ALT levels; hs-CRP levels only show a reduction trend.

4 April 2016 in Endocrine Research
Verified
Journal Article
Closed access
PDF file
LSLuis E. Simental-Mendía
Luis E. Simental-Mendía
ESEsteban Simental-Mendía
Esteban Simental-Mendía
MRMartha Rodríguez-Morán
Martha Rodríguez-Morán
Fernando Guerrero-RomeroFernando Guerrero-Romero
Fernando Guerrero-Romero
Aim: To determine whether hyperuricemia is associated with the early phase and late phase of insulin release in apparently healthy non-obese subjects with normal glucose tolerance. Materials and methods: A population-based cross-sectional study was performed. Apparently healthy individuals aged 20 to 65 years were eligible to participate. Smoking, alcohol intake ≥30 g per day, obesity, glomerulopathies, hepatic disease, malignancy, cardiovascular disease, and medical treatment in the last 3 months, were exclusion criteria. Hyperuricemia was defined by fasting uric acid levels ≥6 mg/dL and ≥7 mg/dL for women and men, respectively. Insulin release was evaluated by estimating the early and late phases of insulin release. The association between hyperuricemia (independent variables) and insulin release (dependent variables) was estimated using multiple linear regression analysis. Results: A total of 123 subjects, without significant differences in age (32.4 ± 12.8 and 34.7 ± 9.9 y), body mass index (25.3 ± 3.7 and 24.7 ± 3.0 kg/m2), and waist circumference (94.6 ± 9.7 and 90.2 ± 9.3 cm), were allocated into the groups with (n = 25) and without (n = 98) hyperuricemia. The linear regression model, adjusted by HOMA-IR and triglyceride levels, showed a significant association of hyperuricemia with both the early phase (B = 508.8; 95%CI 253.3–764.4, p<0.001) and late phase of insulin release (B = 35.0; 95%CI 8.7–61.3, p = 0.009). Conclusions: Hyperuricemia is associated with the increase of early and late phases of insulin release in apparently healthy non-obese subjects with normal glucose tolerance.

1 September 2008
Verified
Journal Article
Closed access
JCJosé A Curiel-García
José A Curiel-García
MRMartha Rodríguez-Morán
Martha Rodríguez-Morán
Fernando Guerrero-RomeroFernando Guerrero-Romero
Fernando Guerrero-Romero

1 March 2010 in Revista Panamericana de Salud Pública
Verified
Journal Article
Closed access
PDF file
Fernando Guerrero-RomeroFernando Guerrero-Romero
Fernando Guerrero-Romero
MRMartha Rodríguez-Morán
Martha Rodríguez-Morán
To validate a method for screening cases of type 2 diabetes and monitoring at-risk people in a community in northern Mexico. The screening instrument for type 2 diabetes (ITD, for its Spanish acronym) was developed using a multiple logistic regression analysis that made it possible to determine the association between a new diagnosis of diabetes (a dependent variable) and 11 known risk factors. Internal validations were performed (through v-fold cross-validation), together with external validations (through the monitoring of a cohort of healthy individuals). In order to estimate the relative risk (RR) of developing type 2 diabetes, the total ITD score is calculated on the basis of an individual's risk factors and compared against a curve that shows the probability of that individual developing the disease. Of the 525 people in the cohort, 438 (83.4%) were followed for an average of 7 years (4.5 to 10 years), for a total of 2 696 person-years; 62 (14.2%) people developed diabetes during the time they were followed. Individuals scoring 55 points based on their risk factors demonstrated a significantly higher risk of developing diabetes in 7 years (RR = 6.1; IC95%: 1.7 to 11.1); the risk was even higher for those with a score of 75 points (RR = 9.4; IC95%: 2.1 to 11.5). The ITD is easy to use and a valid screening alternative for type 2 diabetes. Its use will allow more individuals to benefit from disease prevention methods and early diagnosis without substantially increasing costs and with minimal use of laboratory resources.

1 February 2015 in Clinical Nephrology
Verified
Journal Article
Closed access
GZGraciela Zambrano-Galvan
Graciela Zambrano-Galvan
MRMiguel Reyes Romero
Miguel Reyes Romero
BLBrissia Lazalde
Brissia Lazalde
MRMartha Rodríguez-Morán
Martha Rodríguez-Morán
Fernando Guerrero-RomeroFernando Guerrero-Romero
Fernando Guerrero-Romero
To evaluate a predictive model of microalbuminuria by using anthropometric, clinical and genetic variables in relatives of subjects with diabetic nephropathy.